Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 7, 2017; 23(29): 5324-5332
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5324
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5324
Table 1 Demographic features of study subject n (%)
Characteristics | UC patients | Non IBD control |
No. of patients (total) | 8 | 8 |
Sex (M/F) | 3/5 | 2/6 |
Age (mean ± SD, range, yr) | 39.75 ± 10.29 (25-62) | 40.75 ± 11.86 (24-60) |
Disease duration (mean ± SD, Range, yr) | 6.35 ± 6.52 (1.5-21) | NA |
Disease extent | ||
Proctitis | 3 (37.5) | |
Left sided colitis | 5 (62.5) | |
Medication | ||
Mesalamine | 5 (62.5) | 0 |
Azathioprine | 3 (37.5) | 0 |
Steroids | 0 | 0 |
Table 2 List of primers used for reverse transcription and qRT-PCR
Name | Primer | Sequence (5’-3’) |
Reverse Universal Primer | GTGCAGGGTCCGAGGT | |
hsa-miR-125b-5p | RT | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGTCACAAGT |
Forward | TCCCTGAGACCCTAACTTG | |
hsa-miR-223-3p | RT | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGTGGGGTAT |
Forward | TGTCAGTTTGTCAAATACCC | |
hsa-miR-155-5p | RT | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCCTAT |
Forward | TTAATGCTAATCGTGATAGG | |
hsa-miR-138-5p | RT | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGCGGCCTGA |
Forward | AGCTGGTGTTGTGAATCAG | |
hsa-miR-200a-3p | RT | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACATCGTT |
Forward | TAACACTGTCTGGTAACGAT | |
hsa-miR-378d | RT | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGTTTCTGTC |
Forward | ACTGGACTTGGAGTCAGAAA | |
Sno RNA U6 | RT | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAAAATATG |
Forward | CAAATTCGTGAAGCGTTCCA |
Table 3 List of top 44 differentially expressed miRNAs in the inflamed colonic mucosal biopsies of ulcerative colitis patients determined by microarray
MicroRNA | F.C1 | Expression | MicroRNA | F.C | Expression |
hsa-miR-138-5p | 35.16 | Upregulated | hsa-miR-148a-5p | 2.42 | Upregulated |
hsa-miR-708-5p | 34.7 | Upregulated | hsa-miR-155-5p | 2.33 | Upregulated |
hsa-miR-212-3p | 24.06 | Upregulated | hsa-miR-21-5p | 1.81 | Upregulated |
hsa-miR-4538 | 26.12 | Upregulated | hsa-miR-196b-3p | 1.50 | Upregulated |
hsa-miR-4521 | 17.69 | Upregulated | hsa-miR-552-3p | -7.82 | Downregulated |
hsa-miR-4417 | 16.63 | Upregulated | hsa-miR-196b-5p | -7.60 | Downregulated |
hsa-miR-17-3p | 15.28 | Upregulated | hsa-miR-378d-5p | -4.06 | Downregulated |
hsa-miR-424-3p | 14.17 | Upregulated | hsa-miR-141-3p | -3.03 | Downregulated |
hsa-miR-874-3p | 13.47 | Upregulated | hsa-miR-10b-5p | -2.85 | Downregulated |
hsa-miR-25-5p | 13.41 | Upregulated | hsa-miR-215-5p | -2.56 | Downregulated |
hsa-miR-223-3p | 13.01 | Upregulated | hsa-miR-192-5p | -2.52 | Downregulated |
hsa-miR-1271-5p | 11.96 | Upregulated | hsa-miR-194-3p | -2.31 | Downregulated |
hsa-miR-148b-3p | 11.31 | Upregulated | hsa-miR-422a | -2.22 | Downregulated |
hsa-miR-501-5p | 11.26 | Upregulated | hsa-miR-200a-3p | -2.14 | Downregulated |
hsa-miR-4486 | 10.86 | Upregulated | hsa-miR-378a-3p | -2.04 | Downregulated |
hsa-miR-224-3p | 10.46 | Upregulated | hsa-miR-6732-5p | -1.94 | Downregulated |
hsa-miR-21-3p | 8.46 | Upregulated | hsa-miR-147b | -1.78 | Downregulated |
hsa-miR-146b-5p | 6.83 | Upregulated | hsa-miR-200b-3p | -1.7 | Downregulated |
hsa-miR-149-5p | 6.24 | Upregulated | hsa-miR-572 | -1.63 | Downregulated |
hsa-miR-31-5p | 4.04 | Upregulated | hsa-miR-4649-5p | -1.61 | Downregulated |
hsa-miR-491-5p | 3.92 | Upregulated | hsa-miR-638 | -1.6 | Downregulated |
hsa-miR-125b-5p | 2.56 | Upregulated | hsa-miR-299-5p | -1.59 | Downregulated |
Table 4 List of potential targets and the pathway involved
MicroRNA | Target gene | Pathway involved |
hsa-miR-155-5p | TAB2, CFLAR, CARD11, | NF-κB signaling. |
ReLA, TRAF3 | ||
hsa-miR-155-5p | CARD6, ERBB2IP, MAPK10 | Nod like receptor signaling |
hsa-miR-155-5p | S °CS1, KRAS, PAK2, RAP1B, | MAPK signaling |
RFLA, TAOK1, CACNB4, BDNF | ||
hsa-miR-155-5p | FOS, S °CS1, IKBKE, TRAF3, | TLR signaling |
MAPK10, TAB2 | ||
has-miR-155 | NFAT5, GSK3B, INPP5D, VAV3, PIK3CA | B cell receptor signaling |
hsa-miR-138-5p | CSNK2A2, RELA | NF-κB signaling |
hsa-miR-138-5p | CXCL8, MAP2K7 | TLR signaling |
hsa-miR-138-5p | CLDN19, CD274, ITGAL | Cell Adhesion Molecules. |
hsa-miR-125b-5p | MAPK14, JUN.AKT1, IRAK1, TRAF6, IRF5 | TLR signaling |
hsa-miR-125b | TNFAIP3, CSNK2A1, IRAK1 | NF-κB signaling |
hsa-miR-223-3p | STAT1, RELA | TLR signaling |
hsa-miR-223-3p | TAB3, ERC1, PARP1, RELA | NF-κB signaling |
hsa-miR-378d | MAPK1 | MAPK signaling |
hsa-miR-378d | TRAF3 | NF-κB signaling |
hsa-miR-200a | TAB2, TNFAIP3 | NF-κB signaling |
- Citation: Valmiki S, Ahuja V, Paul J. MicroRNA exhibit altered expression in the inflamed colonic mucosa of ulcerative colitis patients. World J Gastroenterol 2017; 23(29): 5324-5332
- URL: https://www.wjgnet.com/1007-9327/full/v23/i29/5324.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i29.5324